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Kawasaki disease is an acute febrile, systemic vasculitic
syndrome of an unknown etiology that primarily occurs in
children younger than five years of age. The principal presen-
tations of Kawasaki disease include fever, bilateral nonexu-
dative conjunctivitis, erythema of the lips and oral mucosa,
changes in the extremities, rash, and cervical lymphadeno-
pathy. Coronary artery aneurysms or ectasia develops in 15%
to 25% of untreated children with the disease, which may later
lead to myocardial infarction, sudden death, or ischemic heart
disease. Treatment with intravenous gamma globulin (IVIG)
is effective, but the mode of action is still unclear. The
development of a diagnostic test, a more specific therapy, and
ultimately the prevention of this potentially fatal illness in
children are all dependent upon the continued advances in
determining the etiopathogenesis of this fascinating disorder.
Key Words: Kawasaki disease
HISTORICAL BACKGROUND
Tomisaku Kawasaki saw his first case of an
unusual illness in a four-year-old child with a rash
and fever at the Red Cross Hospital in Tokyo, Japan
in January of 1961. He published his first report
on 50 similar Japanese patients in 1967.1
Initially, he believed that the clinical syndrome
was a benign, self-limited process with no
sequelae. Noboru Tanaka, a pathologist, dis-
covered coronary artery thrombosis during an
autopsy on a child who was previously diagnosed
by Kawasaki as having the disorder. Takajiro
Yamamoto, a pediatrician, noted that one of his
patients with the clinical stigmata of the typical
Kawasaki disease had a gallop rhythm associated
with congestive heart failure. Yamamoto and
colleagues2 published a report on 23 patients, of
whom 11 (48%) had abnormalities detected by an
electrocardiogram. These results persuaded
Yamamoto that cardiac involvement was a com-
mon feature of this syndrome. The first Japanese
nationwide survey was published in 1970 and
documented ten autopsy cases of sudden cardiac
death resulting from complications of coronary
artery aneurysms after Kawasaki disease.3
It was not until 1974 that the first description
of this disorder was published in the English
language literature.4 The disease is now known to
occur in both endemic and community-wide
epidemic forms in children of all races in the
Americas, Europe, and Asia. Although an infec-
tious agent is suspected, the cause remains un-
known. However, significant progress has been
made towards understanding the natural history
of the disease and in the development of thera-
peutic interventions that halt the immune-
mediated destruction of the arterial wall.
DIAGNOSIS
In the absence of a specific diagnostic test or
pathognomonic clinical feature, clinical criteria
have been established to assist physicians in
diagnosing Kawasaki disease. The syndrome is
currently diagnosed by the use of a case definition
that was initially created for epidemiological
surveys (Table 1). In many cases, however, the
clinical criteria for Kawasaki disease are not all
present on any given day. The lack of a specific
Kawasaki Disease
Dong Soo Kim
Division of Infectious Disease and Immunology, Department of Pediatrics, Yonsei University College of Medicine, Severance
Children's Hospital, Seoul, Korea.
Received November 9, 2006
Reprint address: requests to Dr. Dong Soo Kim, Division of
Infectious Disease and Immunology, Department of Pediatrics,
Yonsei University College of Medicine, Severance Children's
Hospital, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752,
Korea. Tel: 82-2-2228-2057, Fax: 82-2-393-9118, E-mail: dskim
6634@yumc.yonsei.ac.kr
Review Article
Table 1. Diagnostic Criteria for Kawasaki Disease
Fever lasting for at least five days
At least four of the five following symptoms
Bilateral bulbar conjunctival injection
Changes in the mucosa of the oropharynx
Changes of the peripheral extremities
Polymorphous rash
Cervical adenopathy ( 1.5 cm diameter)
Illness not explained by other known disease
processes
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and sensitive diagnostic test remains a major
obstacle to correctly identifying all patients with
Kawasaki disease.
Principal clinical findings
A remittent fever, often 40 or higher, is
characteristic of the acute phase and usually
heralds the onset of illness. The fever is un-
responsive to antibiotics but partially responds to
antipyretics. In untreated children, the febrile
period lasts on average approximately ten days,
but may range from 5 to 25 days.
Bilateral conjunctival injection typically involves
the bulbar conjunctivae, is not accompanied by
suppuration (Fig. 1A), and it usually begins
shortly after the onset of fever.
The most characteristic changes are the bright
red, swollen lips with vertical cracking and
bleeding (Fig. 1B). The mucosa of the oropharynx
may be bright red, and the tongue may have a
typical "strawberry" appearance.
The erythematous rash usually appears in the
acute phase of the disease and lasts from one or
two days to a week or more. The rash varies over
time and is characteristically located on the trunk
and may further spread to involve the face,
extremities, and perineum (Fig. 1C). Scarlatini-
form, macular, popular, multiforme, and purpuric
lesions have all been described. The rash,
however, is neither bullous nor vesicular.
Changes in the peripheral extremities include
erythema of the palms and soles, which is often
accompanied by painful, brawny edema of the
dorsa of the hands (Fig. 1D) or feet (Fig. 1E) in
the acute phase of the disease. Desquamation of
the fingers and toes usually begins in the
periungual region within two to three weeks after
the onset of fever and may extend to include the
palms and soles (Fig. 1F).
Cervical lymphadenopathy is the least common
of the principal clinical features. It is usually
unilateral and confined to the anterior cervical
triangle, and its classic criteria include 1 lymph
node that is > 1.5 cm in diameter. Imaging studies
frequently demonstrate multiple enlarged nodes
without suppuration.
Fig. 1. (A) Bilateral, non-exudative conjunctival injection with perilimbal sparing. (B) Strawberry tongue and bright red,
swollen lips with vertical cracking and bleeding. (C) Erythematous rash involving perineum. (D) Erythema of the palms,
which is often accompanied by painful, brawny edema of the dorsa of the hands. (E) Erythema of the soles, and swelling
dorsa of the feet. (F) Desquamation of the fingers. (G) Erythema and induration at the site of a previous vaccination with
Bacille Calmette-Gurin (BCG). (H) Perianal erythematous desquamation.
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Incomplete (atypical) Kawasaki disease
The concept of "incomplete" (atypical) Kawasaki
disease has emerged in recent years. Many
experienced clinicians have encountered patients
with an inflammatory disorder who did not meet
the clinical case definition, but in whom an echo-
cardiogram documented coronary-artery abnor-
malities, thus confirming the diagnosis of
Kawasaki disease. Therefore it may be reasonable
to consider Kawasaki disease as a systemic
vasculitic syndrome having heterogeneous fea-
tures rather than a single clinical entity. Incom-
plete (atypical) Kawasaki disease is more common
in young infants than in older children, and
makes the accurate diagnosis and timely treat-
ment especially important in these young patients
who have a substantial risk of developing coro-
nary abnormalities.5 The conventional diagnostic
criteria should be viewed as guidelines that are
particularly useful in preventing overdiagnosis
but may fail to recognize incomplete forms of the
disease.
Cardiac findings
Cardiovascular manifestations can be promi-
nent in the acute phase of Kawasaki disease and
are the leading cause of long-term morbidity and
mortality. During this phase, the pericardium,
myocardium, endocardium, valves, and coronary
arteries all may be involved. Cardiac auscultation
of the infant or child with Kawasaki disease in the
acute phase often reveals a hyperdynamic pre-
cordium, tachycardia, a gallop rhythm, and an
innocent flow murmur in the setting of anemia,
fever, and depressed myocardial contractility
secondary to myocarditis. Children with signifi-
cant mitral regurgitation may have a pansystolic
regurgitation murmur that is typical of this
condition. Occasionally, patients with Kawasaki
disease and poor myocardial function may have
low cardiac output syndrome or shock.
Noncardiac findings
Multiple noncardiac clinical findings may be
observed in patients with Kawasaki disease.
Children with Kawasaki disease are often times
more irritable than children with other febrile
diseases. Arthritis or arthralgia can occur in the
first week of the disease and are likely to involve
multiple joints, especially the knees and ankles.
Gastrointestinal complaints, including diarrhea,
vomiting, and abdominal pain, occur in approx-
imately one third of the patients. Hepatic enlarge-
ment and jaundice may occur. Acute acalculous
distention of the gallbladder (hydrops) occurs
during the first two weeks of illness and can be
identified by an abdominal ultrasound (Fig. 2).6
Erythema and induration at the site of a previous
vaccination with Bacille Calmette-Gurin (BCG) is
common in patients, especially in those younger
than a year old (Fig. 1G).7,8 These can help with
the early diagnosis of Kawasaki disease along
with perianal erythematous desquamation (Fig.
1H).
Laboratory findings
No specific diagnostic test for Kawasaki disease
exists, but certain laboratory findings are
characteristic. During the acute stage of Kawasaki
disease, leukocytosis is typical with a predomi-
nance of immature and mature granulocytes, and
peripheral lymphocytes are depleted by the
upregulated apoptosis.9,10 Anemia may develop,
usually with normal red blood cell indexes,
particularly with a prolonged duration of active
inflammation. Elevated erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP), and other
acute phase reactants are almost universally
Fig. 2. On the ninth day of Kawasaki disease, acute
acalculous distention of the gallbladder (hydrops) was
identified by an abdominal ultrasound in a one-year-old
boy.
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present in the acute phase of the disease and may
persist for four to six weeks. The platelet count is
generally normal in the first week of the disease
and rapidly increases within the next two weeks,
sometimes exceeding 1,000,000/mm3. The antinu-
clear antibody and rheumatoid factor are not
detectable.
Moderate elevations in serum transaminases
occur in these patients. Hypoalbuminemia is com-
mon and is associated with more severe and more
prolonged acute disease. Urinalysis reveals inter-
mittent sterile pyuria in patients with Kawasaki
disease, although suprapubic urine generally does
not show pyuria, which suggests urethritis.
Cerebrospinal fluid (CSF) is characterized by
pleocytosis with a predominance of mononuclear
cells, as well as normal glucose and protein
levels.11 The synovial fluid has been described as
inflammatory. Plasma lipids are markedly altered
in acute Kawasaki disease, with depressed plasma
cholesterol, high-density lipoprotein (HDL), and
apolipoprotein A-I.12-14
EPIDEMIOLOGY
Kawasaki disease has been reported in all racial
and ethnic groups, as well as across the entire
pediatric age range, although in most cases 85%
of the patients are younger than five years old.
Patients younger than six months or older than
eight years old are encountered infrequently but
may be at risk of having coronary artery an-
eurysms.5,15-17 The frequency of the disease varies
from one part of the world to another. Kawasaki
disease is markedly more prevalent in Japan and
in children of Japanese ancestry, with an annual
incidence of 112 cases per 100,000 children
younger than the age of five.
18
The incidence rates
have been steadily increasing for 11 years since
1987 and the rate had increased by over 1.5 times
by 1998.
18
In the United States, the incidence of
Kawasaki disease has been best estimated by
using hospital discharge data.19,20 An estimated
4,248 hospitalizations associated with Kawasaki
disease occurred in the United States in 2000, with
a median age of these patients being two years
old.19 The race-specific incidence rate, derived
from administrative data, indicate that Kawasaki
disease is most common among Americans of
Asian and Pacific Island descent, intermediate in
non-Hispanic African American and Hispanics,
and lowest in whites.19 Korea has the second
highest incidence rate of Kawasaki disease with 86
cases per 100,000 children who are five years old
or older.21
Rates of recurrence and familial occurrence of
Kawasaki disease are best documented in the
literature from Japan, and are reported to be 3%
and 1%, respectively.22 Within one year after the
onset of the first case in a family, the rate in a
sibling is 2.1%, which is a relative ten-fold risk
when compared to the unaffected Japanese popu-
lation, in which 50% of the second cases develop
within ten days of the first case.23 The risk of
occurrence in twins is 13%.23,24 Higher rates of
Kawasaki disease in the siblings of index cases
and twins suggest a possible role for genetic pre-
disposition that interacts with exposure to the
etiologic agent or agents in the environment.23-25
The reported occurrence of Kawasaki disease in
children of parents who themselves had the
disease in childhood also supports the contribu-
tion of genetic factors.26-28
ETIOLOGY
The cause of Kawasaki disease remains un-
known, although both clinical and epidemiolo-
gical features strongly support an infectious cause.
The peak incidence in the toddler age-group, with
only rare cases in infants younger than three
months of age and in adults, suggests a role for
transplacental antibodies conferring protection
and that the development of protective immunity
is a result of asymptomatic infection in most
individuals. Many of the clinical features are
similar to those of other infectious diseases, such
as adenovirus infection and scarlet fever.
However, efforts to identify an infectious agent in
Kawasaki disease with conventional bacterial and
viral cultures, serological methods, as well as with
animal inoculation, have failed to identify an
infectious cause.
A controversial hypothesis has been proposed
that Kawasaki disease is related to a bacterial
superantigenic toxin because of the reported
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selective expansion of V 2 and V 8 T-cell receptorβ β
families.29-31 Recently, a multicenter, prospective
study detected no difference in the rates of isola-
tion of superantigen-producing bacteria between
patients with the syndrome and febrile controls.32
Other investigators have found evidence of an
oligoclonal antibody response and this suggests a
conventional antigen.33-35
A genetic influence on disease susceptibility is
suspected because Kawasaki disease is over-rep-
resented among Asian and Asian-American
populations. There have been attempts to link
susceptibility to Kawasaki disease or disease
outcome to allelic variations.36-46 To date, only
small cohorts of children have been analyzed in
association studies in which the frequencies of
the alleles of interest have been compared
between Kawasaki disease and control indi-
viduals. The insufficient sample sizes of these
studies preclude any general conclusions and
additional studies are needed.
PATHOLOGY
Kawasaki disease causes severe vasculitis of all
blood vessels but predominantly affects the
medium-sized arteries, with predilection for the
coronary arteries. The early stages of the forma-
tion and development of arteritis in Kawasaki
disease have been well studied morphologically
in relatively large muscular arteries.47 The media
of affected vessels demonstrate edematous disso-
ciation of the smooth muscle cells, which is most
obvious outwardly. Endothelial cell swelling and
subendothelial edema are seen, but the internal
elastic lamina remains intact. An influx of neutro-
phils is found in the early stages (seven to nine
days after onset), with a rapid transition to large
mononuclear cells in concert with lymphocytes,
predominantly CD8+ (cytotoxic) T cells.48 IgA-
secreting plasma cells are also found in the vessel
wall as the inflammation progresses.34 Destruc-
tion of the internal elastic lamina and eventually
fibroblastic proliferation occur at this stage.
Table 2. Evidence of Immune System Activation in Kawasaki Disease
1. Cytokines
TNF- ,α β50,63
p60 soluble TNF-R119
IL-1β51
IL-2, soluble IL-2R62,65
IL-4,64 6,52,63 8,63 10,64 15,53 17,54 1855
IFN- ,α γ62
TGF- ( )β
120
2. Chemokines
MIP-161
MCP-1β61
MIF121
RANTES61
3. Monocyte/macrophages
Increased number of activated cells50
TLR266
VEGF60
4. B lymphocytes
Increased number of activated B cells spontaneously secreting immunoglobulin35
Cytotoxic IgM antibodies vs. endothelial cells stimulated by cytokines122
Circulating immune complex122,123
Antibodies vs. EBV,
124
65kD HSP,
7
thrombin-III,
125
ANCA
126
Oligoclonal expansion of V IIIκ 30, and VH
35
CD5+ B cells ( )9,35
5. T lymphocytes
DR+ CD4, and CD8+33
V 2 and V 8 T cellsβ β
29,30
CD40L59
ANCA indicates anti-neutrophil cytoplasmic antibodies; CD40L, CD40 ligand; EBV, Epstein-Barr virus; HSP, heat shock protein; IL,
interleukin; IL-2R, IL-2 receptor; INF, interferon; MCP, monocyte chemoattractant protein; MIF, macrophage migration inhibitory factor;
MIP, macrophage inflammatory protein; RANTES, regulated upon activation normal T cell expressed and secreted; TGF, transforming
growth factor; TLR2, toll-like receptor 2; TNF, tumor necrosis factor; TNF-R, tumor necrosis factor receptor; VEGF, vascular endothelial
growth factor.
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Matrix metalloproteinases (MMPs) are prominent
in the remodeling process. Active inflammation is
replaced with scar formation over the course of
several weeks to months by progressive fibrosis.49
IMMUNOPATHOGENESIS
Striking immune perturbations occur in acute
Kawasaki disease, including marked cytokine
cascade stimulation and endothelial cell activation
(Table 2). Concentrations of many proinflamma-
tory cytokines and chemokines, including tumor
necrosis factor (TNF ), and interleukin (IL)s 1,α α
6, 8, 15, 17 and 18, are higher than normal during
the acute phase of the disease.50-55 The key steps
leading to coronary arteritis are still being clari-
fied, but endothelial cell activation, CD68+ mono-
cyte/macrophages, CD8+ T lymphocytes, and
oligoclonal IgA plasma cells appear to be in-
volved.34,48,56 The prominence of IgA plasma cells
in the respiratory tract, which is similar to
findings in fatal viral respiratory infections, sug-
gests a respiratory portal of entry of an etiologic
agent or agents.57 Enzymes, including MMPs, that
are capable of damaging arterial wall integrity
may be important in the development of aneu-
rysmal dilatation.58 A role for MMPs in this
process is suggested on the basis of high serum
concentrations of these enzymes during acute
Kawasaki disease and immunolocalisation of
MMP9 and MMP2 in the arterial wall of the
lesions.49,58 CD40 ligands (CD40L, CD154, and
gp39), vascular endothelial growth factor (VEGF),
monocyte chemotactic and activating factor
(MCAF or MCP-1), and various interleukins also
appear to play important roles in the vasculitic
process.59-65 Increased expression of toll-like recep-
tor 2 (TLR 2) suggests that the innate immune
response may be associated with the pathogenesis
of Kawasaki disease.
66
Fig. 3 illustrates the pro-
posed events in the evolution of vasculitis in
Kawasaki disease.
TREATMENT
Treatment of Kawasaki disease in the acute
phase is directed at reducing the inflammation in
the coronary artery wall and preventing coronary
thrombosis, whereas long-term therapy in indi-
viduals who develop coronary aneurysms is
aimed at preventing myocardial ischemia or
infarction.
Aspirin
Aspirin has been used to reduce inflammation
and to inhibit platelet aggregation in children
with Kawasaki disease, but it does not seem to
decrease the number of patients who develop
coronary abnormalities.67 Whether other non-
steroidal anti-inflammatory agents might be less
toxic and have a greater anti-inflammatory effect
has not been studied. Currently, high doses of
aspirin (80-100 mg/kg daily divided into four
doses) are used during the acute inflammatory
stage of the disease. Practices regarding the dura-
tion of high-dose aspirin administration vary
across institutions, and many centers reduce the
dose of aspirin to a single daily dose of 3-5 mg/kg
after the child has been afebrile for 48 to 72 hours.
This antiplatelet dose is continued until the
patient shows no evidence of coronary changes
within six to eight weeks after the onset of illness.
For children who develop coronary abnormalities,
Fig. 3. Schematic diagram of the pathogenesis of Kawasaki
disease. ADCC indicates antibody-dependent cell-medi-
ated cytotoxicity; AECA, anti-endothelial cell antibodies;
ANCA, anti-neutrophil cytoplasmic antibodies; APC, anti-
gen-presenting cell; CD40L, CD40 ligand; CTL, cytolytic T
lymphocyte; ELAM-1, endothelial-leukocyte adhesion
molecule-1; G-CSF, granulocyte colony stimulating factor;
ICAM-1, intercellular adhesion molecule-1; IFN, inter-
feron; IL, interleukin; HSP, heat shock protein; TNF,
tumor necrosis factor.
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aspirin may be continued indefinitely. Adverse
effects of aspirin include gastrointestinal irritation
and liver-function abnormalities. Children who
take salicylates while they are experiencing an
active infection with varicella or influenza are at
risk for Reye syndrome and this syndrome has
been reported in patients taking high-doses of
aspirin for a prolonged period after Kawasaki
disease. It is unclear whether the low-dose
therapy used for the antiplatelet effect increases
the risk of Reye syndrome. Children who are
taking salicylates long-term should receive an
annual influenza vaccine and their parents should
be instructed to promptly contact their child's
physician if the child develops symptoms of or is
exposed to either influenza or varicella.
Intravenous immunoglobulin (IVIG)
The efficacy of IVIG administered in the acute
phase of Kawasaki disease by reducing the
prevalence of coronary artery abnormalities has
been well established.67-72 The mechanism of
action of IVIG remains unknown, although
theories include cross-linking of the Fc II and Fcγ γ
III receptors on macrophages, induction of the
immune inhibitory receptors, blocking of the
interaction between endothelial cells and natural
killer cells, augmenting the T-cell suppressor
activity, suppression of antibody synthesis, neu-
tralization of bacterial superantigens or other
etiologic agents, and provision of the anti-idio-
typic antibodies. In vitro findings suggest that
IVIG blocks endothelial-cell proliferation and the
synthesis of adhesion molecules, chemokines, and
cytokines.73
A single dose of 2 g/kg IVIG infused over 10-12
h is the current standard of therapy. A variety of
dose regimens have been used. Two meta-
analyses have demonstrated a dose-response
effect, with higher doses given in a single infusion
having the greatest efficacy.67,71 Furthermore, peak
adjusted serum IgG levels are lower among
patients who subsequently develop coronary
artery abnormalities and are inversely related to
fever duration and laboratory indexes of acute
inflammation.69,74 The association of lower peak
IgG levels with worse outcomes lends further
support to the concept of a relationship between
serum IgG concentration and therapeutic effec-
tiveness.
This therapy should be instituted within the
first ten days of illness and when possible within
seven days. Subsequent studies have suggested
that the benefit of therapy is greatest when it is
given early in the illness. An epidemiological
survey of more than 5,000 patients in Japan who
were treated with 2 g/kg IVIG showed that the
patients treated within six days of illness had
fewer cardiac complications one month after the
onset of the syndrome than those treated later in
the course of their illness.75 The benefits of starting
treatment for Kawasaki disease prior to the fifth
day of illness is controversial. Muta et. al.76
reported that starting treatment prior to the fourth
day of the illness was no different than starting
treatment between the fifth and ninth day of
illness in regards to preventing cardiac sequelae.
Any child with Kawasaki disease who has
evidence of persisting inflammation, including
fever or high concentrations of inflammatory
markers with or without coronary artery abnor-
malities, should be treated even if the diagnosis
is made after the tenth day of illness.77
Minor adverse reactions to IVIG vary with the
specific product infused and may include fever,
chills, and hypotension. Administration of live
virus vaccines (measles, mumps, and rubella, or
varicella) should be deferred for at least 11
months after the administration of IVIG due to the
reduced immunogenicity of the vaccine related to
the passive antibodies from the IVIG prepara-
tion.
78
Glucocorticoids
The role of glucocorticoids in the treatment of
Kawasaki disease remains controversial, although
their use is the treatment of choice in other
forms of vasculitis. Corticosteroids were used as
the initial therapy for Kawasaki disease long
before the first report of IVIG efficacy in 1984.
An early study by Kato et al.79 suggested that
steroids exert a detrimental effect when used as
the initial therapy for Kawasaki disease. This
study has been criticized because of the study
design, the small number of patients in the pre-
dnisolone-treated group, and the high frequency
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of aneurysms, but it has profoundly influenced
the treatment of this disease. In a retrospective
review, Shinohara et. al.80 found that the treat-
ment regimens that included prednisolone were
associated with a significantly shorter duration of
fever and a lower prevalence of coronary artery
aneurysms. Most recently, a small randomized
trial examined whether the addition of 30 mg/kg
of intravenous methylprednisolone to conven-
tional therapy with IVIG (2 g/kg) and aspirin
improved outcomes.81 Patients who received
steroids had a shorter duration of fever and
shorter hospital stays, as well as a lower mean
ESR and median CRP six weeks after the onset
of illness. No differences between treatment
groups in coronary outcomes were noted, with
limited statistical power. Children, to whom
corticosteroids and IVIG were administered,
compared with those who received IVIG alone,
had reduced levels of cytokines, including IL-2,
IL-6, IL-8, and IL-10 within 24 hours of IVIG
administration.82
Treatment of patients who failed to respond to
initial therapy
Ten to fifteen percent of the children diagnosed
with Kawasaki disease who are treated with
high-dose aspirin and 2 g/kg IVIG will have a
persistent or recrudescent fever.83,84 Many studies
have shown that children who do not become
afebrile after the first dose of IVIG are at an
increased risk of developing coronary artery
aneurysms.
85
Failure to respond is usually defined
as a persistent or recrudescent fever 36 hours after
the completion of the initial IVIG infusion. Most
experts recommend retreatment with IVIG, at a
dose of 2 g/kg. The putative dose-response effect
of IVIG forms the theoretical basis for this
approach. Corticosteroids also have been used to
treat patients who have failed to respond to the
initial therapy for Kawasaki disease,84,86 although
their effects on coronary artery abnormalities are
still uncertain. The most commonly used steroid
regimen is intravenous pulse methylprednisolone,
with 30 mg/kg for two to three hours, admin-
istered once daily for one to three days. Other
treatments successfully used in children include a
monoclonal antibody against TNF- (infliximab),α
ulinastatin, plasmapheresis, and cytotoxic agents
such as cyclophosphamide and cyclosporine A.87-90
Methotrexate (MTX), a dihydrofolate reductase
inhibitor, has been used for its anti-inflammatory
properties in several vasculitides, and was
reported to be effective in patients who are refrac-
tory to IVIG.91,92 Low-dose oral MTX (10 mg/BSA,
once weekly) resulted in a rapid defervescence
without progression of coronary artery dilatation
(Fig. 4). The mechanism for the anti-inflam-
matory action of MTX is still unclear, but some
proposed mechanisms include the inhibition of
the activity and secretion of proinflammatory
cytokines such as IL-1 and IL-6.
Treatment of cardiovascular complications
The aims of therapy in patients who develop
coronary artery aneurysms are to prevent throm-
bosis and the myointimal proliferation that leads
to stenosis. Only anecdotal experience is avail-
able to determine the course of treatment for
these children. Low-dose aspirin (3-5 mg/kg
daily) has been the mainstay of therapy for
children with small to medium aneurysms (< 8
mm). Use of other antiplatelet agents (e.g.,
clopidogrel and ticlopidine) alone or with aspirin
may be beneficial for some patients.93 Randomised
trials are needed to establish the appropriate role
of low-molecular-weight heparins, monoclonal
antibodies against the platelet IIB/IIIA receptor
(abciximab), and warfarin in the long-term
management of children with giant aneurysms
( 8 mm).
94
Fig. 4. Body temperature in a 7-year-old boy with refrac-
tory Kawasaki disease. After using low-dose oral metho-
trexate (10 mg/BSA, once weekly), body temperature has
returned to normal rapidly.
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PROGNOSIS
Coronary artery aneurysms occur as a sequela
of the vasculitis in 20-25% of untreated children.95
Even when treated with high-dose IVIG regimens
within the first ten days of illness, 5% of children
with Kawasaki disease develop at the least
transient coronary artery dilation and 1% develop
giant aneurysms.67,71,96 Other cardiovascular com-
plications of the syndrome include myocarditis,
pericarditis with effusion, and valvulitis, which
occurs in about 1% of the patients and most
commonly involves the mitral valve.97 Echocar-
diography is a sensitive and reliable method to
detect coronary artery aneurysms in the acute and
subacute stages of the syndrome (Fig. 5A).98,99
Patients with no coronary artery aneurysms
detected by echocardiography during the acute
and subacute phases are clinically asymptomatic
for at least ten years later.100 Coronary angio-
graphy offers a more detailed definition of coro-
nary artery anatomy than the echocardiography,
thus making it possible to detect coronary artery
stenosis or thrombotic occlusion and to also deter-
mine the extent of the collateral artery formation
in patients with Kawasaki disease (Fig. 5B). Aneu-
rysms can occur in arteries outside the coronary
system, most commonly the subclavian, brachial,
axillary, iliac, or femoral vessels, and occasionally
in the abdominal aorta and renal arteries (Fig. 6).97
Many studies have attempted to identify pre-
dictors of coronary artery aneurysms.101-106 Con-
sistent risk factors across these studies include
persistent fever after IVIG therapy, low hemo-
globin concentrations, low albumin concentra-
tions, high white-blood-cell count, high band
count, high CRP concentrations, male sex, and age
less than one year. Thus, laboratory evidence of
increased inflammation combined with demo-
graphic features (male sex, age less than six
months or greater than eight years) and in-
complete response to IVIG therapy create a profile
of a high-risk patient with Kawasaki disease.
Coronary artery lesions resulting from Kawasaki
disease change dynamically with time. Angio-
graphic resolution one to two years after the onset
of the disease has been observed in 50% to 67%
of vessels with coronary aneurysms.100,107 The
likelihood that an aneurysm will resolve appears
to be determined in large measure by the initial
Fig. 6. Abdomial aortogram (A) and a
3D-image of the computed tomogram
(B) showing the aneurysm of the distal
abdominal aorta, just below the origin
of inferior mesenteric artery (IMA) with
an involving bifurcation.
Fig. 5. (A) On the day 35 of Kawasaki
disease, a 2D-echocardiogram demon-
strates an aneurysm of the LCA in a
six-year-old boy. (B) Coronary angio-
gram reveals diffuse dilatation in the
left anterior descending (LAD) branch
of the left coronary artery (LCA) in the
same child.
A B
A B
Dong Soo Kim
Yonsei Med J Vol. 47, No. 6, 2006
size of the aneurysm, in which the smaller aneu-
rysms have a greater likelihood of regression.108,109
Other factors that are positively associated with
the regression of aneurysms include being
younger than a year old at the onset of Kawasaki
disease, fusiform rather than saccular aneurysm
morphology, and an aneurysm location in a distal
coronary segment.107
About 20% of patients who develop coronary
artery aneurysms during the acute disease will
develop coronary artery stenosis100 and might
subsequently need treatment for myocardial is-
chemia, including percutaneous transluminal
angioplasty, rotational atherectomy, coronary
artery stenting, bypass grafting, and even cardiac
transplantation.100,110-113 Whereas aneurysm size
tends to diminish with time, stenotic lesions that
are secondary to marked myointimal proliferation
are frequently progressive.100,114 The prevalence of
stenosis continues to rise almost linearly over
time.100,114 The highest rate of progression to
stenosis occurs among patients with large aneu-
rysms.114 The worst prognosis occurs in children
with giant aneurysms.114-117 In these aneurysms,
thrombosis is promoted by the combination of
sluggish blood flow within the massively dilated
vascular space and the frequent occurrence of
stenotic lesions at the proximal or distal end of the
aneurysms. Myocardial infarction caused by
thrombotic occlusion in an aneurysmal, stenotic,
or both aneurysmal and stenotic coronary artery
is the principal cause of death from Kawasaki
disease.
118
The highest risk of myocardial infarc-
tion occurs in the first year after the onset of the
disease, and the most fatal attacks are associated
with an obstruction in either the left main
coronary artery (LMCA) or both the right coro-
nary artery (RCA) and the left anterior descending
coronary artery (LAD).118 Serial stress tests and
myocardial imaging are mandatory in the man-
agement of patients with Kawasaki disease and
significant coronary artery disease in order to
determine the need for a coronary angiography
and for surgical or transcatheter intervention.
From a purely clinical perspective, children
without known cardiac sequelae during the first
month of Kawasaki disease appear to return to
their previous (usually excellent) state of health,
without signs or symptoms of cardiac impair-
ment.100 However, identification of the appropriate
follow-up of these children is difficult because no
clear picture has yet emerged of the potential
sequelae of the disease without coronary artery
aneurysms. Meaningful knowledge about long-
term myocardial function, late-onset valvar regur-
gitation, and coronary artery status in this
population must await their careful surveillance
in future decades.
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